Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rheumatology (Oxford) ; 47(5): 718-23, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18400833

RESUMO

OBJECTIVE: To examine the distribution of traditional and novel risk factors of cardiovascular disease (CVD) in patients with PsA compared with healthy controls. METHODS: We compared risk factors for CVD between 102 consecutive PsA patients and 82 controls, adjusting for BMI. We also assessed the role of inflammation on the CVD risk factor by using a BMI and high-sensitivity CRP (hsCRP)-adjusted model. RESULTS: The BMI of PsA patients were significantly higher than healthy controls. After adjusting for the BMI, PsA patients still have a higher prevalence of diabetes mellitus (DM) [odds ratio (OR) 9.27, 95% CI 2.09, 41.09) and hypertension (OR 3.37, 95% CI 1.68, 6.72), but a lower prevalence of low high density lipoprotein (HDL) cholesterol (OR 0.16, 95% CI 0.07, 0.41). PsA patients have significantly increased systolic and diastolic blood pressures, insulin resistance and inflammatory markers (hsCRP and white cell count) compared to controls. PsA patients have higher HDL cholesterol and apolipoprotein (Apo) A1 levels; and lower total cholesterol (TC) and low density lipoprotein cholesterol levels; and a lower TC/HDL ratio. However, the Apo B level (P < 0.05), and the Apo B/Apo A1 ratio (P = 0.07) were higher in PsA patients. Further adjustment for hsCRP level rendered the differences in the prevalence of hypertension and DM; the TC, and sugar levels; and white cell count non-significant between the two groups; while the differences in other parameters remained significant. CONCLUSION: These data support the hypothesis that PsA may be associated with obesity, hypertension, dyslipidaemia and insulin resistance because of the shared inflammatory pathway.


Assuntos
Artrite Psoriásica/complicações , Doenças Cardiovasculares/complicações , Adulto , Apolipoproteínas A/análise , Apolipoproteínas B/análise , Artrite Psoriásica/sangue , Artrite Psoriásica/imunologia , Biomarcadores/sangue , Índice de Massa Corporal , Proteína C-Reativa/análise , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/imunologia , Estudos de Casos e Controles , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Estudos Transversais , Diabetes Mellitus/sangue , Diabetes Mellitus/imunologia , Dislipidemias/sangue , Dislipidemias/complicações , Dislipidemias/imunologia , Feminino , Humanos , Hipertensão/sangue , Hipertensão/complicações , Hipertensão/imunologia , Inflamação , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/complicações , Obesidade/imunologia , Prevalência , Medição de Risco/métodos
2.
Hong Kong Med J ; 11(6): 515-9, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16340031

RESUMO

We report a case of disseminated cutaneous Mycobacterium chelonae infection. A patient with dermatomyositis associated with malignancy presented with features of panniculitis. This was later confirmed to be cutaneous Mycobacterium chelonae infection. Disseminated cutaneous Mycobacterium chelonae infection and panniculitis are reviewed.


Assuntos
Dermatomiosite/diagnóstico , Imunossupressores/efeitos adversos , Metotrexato/efeitos adversos , Infecções por Mycobacterium não Tuberculosas/diagnóstico , Mycobacterium chelonae , Paniculite/diagnóstico , Antineoplásicos Hormonais/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Diagnóstico Diferencial , Feminino , Humanos , Hidroxicloroquina/uso terapêutico , Imunossupressores/uso terapêutico , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Prednisolona/uso terapêutico , Pele
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...